Vectura has significant oral technology and manufacturing expertise and capabilities. Our manufacturing facility in Lyon, France,has cGMP status with approvals from the European Medicines Agency, the FDA, ANVISA (Brazil) and KFDA (South Korea), amongst others. The site currently manufactures seven oral products for partners.

Focusing on maximising the value of the facility, Vectura continues to leverage the under capacity of this high-quality manufacturing site with increasing business development volumes being achieved. Whilst Vectura’s investment in the site continues to be modest, we believe that over time the site will become a well-utilised, fully integrated development, manufacturing and packaging contract organisation.

Five of the products manufactured use the GeomatrixTM family of technologies: Diclofenacratiopharm Uno®, Coruno®, ZYFLO CR®, Madopar® DR®/Prolopa® and Sular®, whilst LODOTRA®/RAYOS® uses the GeoclockTM chronotechnology. The facility also manufactures Triglide®, which utilises the Group’s solubilisation technology.

Total underlying revenue for 2017
from oral and non-inhaled
£24.3m
(2016: £23.7m)

Find out more on the Skyepharma website www.skyepharma.fr